Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction

Published:2017-04 Issue:4 Volume:5 Page:305-309
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Luo Nancy,Fonarow Gregg C.,Lippmann Steven J.,Mi Xiaojuan,Heidenreich Paul A.,Yancy Clyde W.,Greiner Melissa A.,Hammill Bradley G.,Hardy N. Chantelle,Turner Stuart J.,Laskey Warren K.,Curtis Lesley H.,Hernandez Adrian F.,Mentz Robert J.,O’Brien Emily C.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

2. Crossing the Quality Chasm: A New Health System for the 21st Century,2001

3. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations;Feldman;JAMA,2016

4. Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure;Fonarow;JAMA Cardiol,2016

5. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Initiative Increasing GDMT Use Among Patients With Heart Failure With Reduced Ejection Fraction;JACC: Heart Failure;2024-08

2. General physicians' perspectives on SGLT2 inhibitors for heart failure;Internal Medicine Journal;2024-07-03

3. Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin;European Journal of Clinical Pharmacology;2024-06-10

4. Impact of Insurance Status and Region on Angiotensin Receptor–Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations;JACC: Heart Failure;2024-05

5. Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction and Acuity Spectra in Heart Failure;JACC: Heart Failure;2024-03